Trial record 1 of 1 for: nct00605514
Previous Study | Return to List | Next Study
Ebola and Marburg Virus Vaccines
This study has been completed.
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:
National Institutes of Health Clinical Center (CC)
First received: January 29, 2008
Last updated: January 24, 2017
Last verified: June 21, 2010
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||June 21, 2010|
|Primary Completion Date:||June 21, 2010 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE; VRC 206 Study Team.. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015 Feb 15;211(4):549-57. doi: 10.1093/infdis/jiu511. Epub 2014 Sep 14.